| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.16B | 17.50 | 21.60 | 65.15% | 42.87% | 48.57% | 2.64% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 83.24M | 2.80 | -0.22 | -49.37% | 0.24 | |||
| ALGSAligos Therapeutics, Inc. | 44.22M | 8.26 | -0.39 | -74.6% | -32.68% | -120.37% | ||
| INOInovio Pharmaceuticals, Inc. | 108.55M | 1.58 | -0.40 | -73.83% | -592.82% | -115.42% | 0.17 | |
| BRNSBarinthus Biotherapeutics plc | 29.81M | 0.73 | -0.47 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.3M | 1.11 | -0.65 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 165.7M | 8.86 | -0.76 | -170.84% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 658K |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 123.55K | 72.32K | 461.69K | 708.92K | 747.65K | 559.8K | 512.67K | 1.24M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | 1.88% |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | -708.92K | -747.65K | -559.8K | -512.67K | -580K |
| Gross Margin % | - | - | - | - | - | - | - | - | - | -0.88% |
| Gross Profit Growth % | - | - | - | - | - | - | -0.05% | 0.25% | 0.08% | -0.13% |
| Operating Expenses | 2.9M | 3.09M | 6.8M | 20.61M | 22.69M | -2.28M | 10.86M | 11.06M | 9.71M | 8.06M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | 12.25% |
| Selling, General & Admin | 871.81K | 1.07M | 1.4M | 1.38M | 2.81M | 5.02M | 7.63M | 5.3M | 4.5M | 2.53M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | 3.84% |
| Research & Development | 1.91M | 2.44M | 5.58M | 19.27M | 19.88M | 16.01M | 3.25M | 5.76M | 5.21M | 5.53M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | 8.41% |
| Other Operating Expenses | -726K | -416K | -186K | -38.24K | 0 | -23.31M | -12K | 0 | -9K | 0 |
| Operating Income | -2.9M | -3.09M | -6.8M | -20.61M | -22.69M | 2.28M | -10.87M | -11.06M | -9.71M | -8.64M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | -13.13% |
| Operating Income Growth % | -0.39% | -0.06% | -1.2% | -2.03% | -0.1% | 1.1% | -5.77% | -0.02% | 0.12% | 0.11% |
| EBITDA | -2.74M | -2.93M | -6.67M | -20.54M | -22.23M | 2.75M | -10.4M | -10.5M | -9.19M | -6.99M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | -10.62% |
| EBITDA Growth % | -0.43% | -0.07% | -1.28% | -2.08% | -0.08% | 1.12% | -4.78% | -0.01% | 0.12% | 0.24% |
| D&A (Non-Cash Add-back) | 161.62K | 162.32K | 123.55K | 72.32K | 461.69K | 468.56K | 471K | 562K | 514K | 1.65M |
| EBIT | -2.9M | -3.09M | -6.8M | -20.61M | -22.69M | 2.28M | -10.86M | -11.06M | -9.71M | -8.64M |
| Net Interest Income | 2.82K | 14.28K | 5.17K | -2.43M | -4.27M | -348K | -3.36M | 3.05M | 115K | -1.34M |
| Interest Income | 2.83K | 14.38K | 5.04K | 1.35M | 8.3K | 582 | 929 | 8.1M | 122.68K | 100.47K |
| Interest Expense | 8 | 100 | 20.45K | 3.78M | 4.28M | 348.93K | 3.36M | 5.05M | 7.98K | 1.44M |
| Other Income/Expense | 283.33K | 704.94K | -3.13M | -2.85M | -8.93M | -3.67M | 2.67M | 5.26M | 3.21M | 13.43M |
| Pretax Income | -2.62M | -2.38M | -9.93M | -23.46M | -31.62M | -1.39M | -8.21M | -5.8M | -6.5M | 4.8M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | 7.29% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -2.62M | -2.38M | -9.93M | -23.46M | -31.62M | -1.39M | -8.21M | -5.8M | -6.5M | 4.8M |
| Net Margin % | - | - | - | - | - | - | - | - | - | 7.29% |
| Net Income Growth % | -0.31% | 0.09% | -3.17% | -1.36% | -0.35% | 0.96% | -4.92% | 0.29% | -0.12% | 1.74% |
| Net Income (Continuing) | -2.62M | -2.38M | -9.93M | -23.46M | -31.62M | -1.39M | -8.21M | -5.8M | -6.5M | 4.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -396880.00 | -282320.00 | -790280.00 | -999999.00 | -999999.00 | -12.40 | -80.00 | -30.80 | -16.80 | 6.00 |
| EPS Growth % | 0.32% | 0.29% | -1.8% | -0.82% | -0.08% | 1% | -5.45% | 0.61% | 0.45% | 1.36% |
| EPS (Basic) | -396880.00 | -282320.00 | -790280.00 | -999999.00 | -999999.00 | -12.40 | -87.60 | -30.80 | -16.80 | 6.00 |
| Diluted Shares Outstanding | 26.38K | 33.77K | 50.26K | 65.36K | 81.66K | 110.81K | 141.14K | 188.52K | 390.66K | 806.37K |
| Basic Shares Outstanding | 26.38K | 33.77K | 50.26K | 65.35K | 81.66K | 110.81K | 102.57K | 188.52K | 390.66K | 806.37K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.48M | 6.78M | 21.64M | 20.55M | 21.17M | 3.31M | 17.84M | 14.37M | 5.45M | 2.39M |
| Cash & Short-Term Investments | 9.11M | 6.57M | 20.51M | 20.29M | 20.98M | 2.93M | 17.37M | 14.07M | 4.87M | 1.96M |
| Cash Only | 8.59M | 4.08M | 20.51M | 20.29M | 20.98M | 2.93M | 17.37M | 14.07M | 4.87M | 1.96M |
| Short-Term Investments | 517.39K | 2.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 71.22K | 325.15K | 0 | 330K | 217K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 120.37 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 360.07K | 198.3K | 911.89K | 102.42K | 101.06K | 33 | -84.15K | 250K | 176K | 131K |
| Total Non-Current Assets | 1.12M | 1.03M | 1.84M | 7.75M | 12.34M | 14.4M | 14.19M | 12.7M | 12.03M | 11.06M |
| Property, Plant & Equipment | 524.57K | 374.53K | 1.58M | 7.55M | 12.19M | 14.25M | 14.19M | 12.7M | 12.03M | 11.06M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.06x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 525.6K | 532.08K | 0 | 0 | 0 | 147.31K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 73.66K | 124.07K | 252.9K | 197.88K | 150.16K | -150 | 0 | 0 | 0 | 0 |
| Total Assets | 10.6M | 7.82M | 23.48M | 28.3M | 33.52M | 17.71M | 32.04M | 27.07M | 17.47M | 13.45M |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.05x |
| Asset Growth % | 1.24% | -0.26% | 2% | 0.21% | 0.18% | -0.47% | 0.81% | -0.16% | -0.35% | -0.23% |
| Total Current Liabilities | 436.03K | 356.88K | 1.98M | 5.83M | 5.49M | 19.97M | 2.44M | 2.34M | 1.78M | 1.81M |
| Accounts Payable | 238.93K | 178.05K | 1.79M | 5.54M | 4.94M | 581.19K | 999K | 716K | 535K | 376K |
| Days Payables Outstanding | - | - | 5.28K | 27.97K | 3.91K | 299.24 | 487.71 | 466.84 | 380.89 | 110.86 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 18.8M | 248.36K | 0 | 396K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 225K |
| Other Current Liabilities | 0 | -190 | 0 | 0 | 0 | 0 | -248.36K | 0 | -396K | 0 |
| Current Ratio | 21.74x | 19.01x | 10.94x | 3.53x | 3.86x | 0.17x | 7.30x | 6.15x | 3.06x | 1.32x |
| Quick Ratio | 21.74x | 19.01x | 10.94x | 3.53x | 3.86x | 0.17x | 7.30x | 6.15x | 3.06x | 1.32x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.56M | 809.54K | 5.33M | 30.82M | 46.87M | 2.28M | 28.61M | 26.49M | 20.26M | 1.67M |
| Long-Term Debt | 0 | 0 | 0 | 25.23M | 35.84M | 0 | 27.16M | 20.08M | 19.37M | 260K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.97M | 1.89M | 1.45M | 1.08M | 797K | 1.4M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.56M | 809.54K | 5.33M | 5.59M | 9.06M | 382.69K | 30.52K | 5.33M | 96K | 3K |
| Total Liabilities | 1.99M | 1.17M | 7.31M | 36.65M | 52.36M | 22.25M | 31.05M | 28.83M | 22.04M | 3.47M |
| Total Debt | 0 | 0 | 0 | 25.23M | 38.02M | 20.9M | 29.23M | 21.54M | 20.56M | 2.09M |
| Net Debt | -8.59M | -4.08M | -20.51M | 4.94M | 17.03M | 17.97M | 11.86M | 7.47M | 15.69M | 122K |
| Debt / Equity | - | - | - | - | - | - | 29.77x | - | - | 0.21x |
| Debt / EBITDA | - | - | - | - | - | 7.60x | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | 6.53x | - | - | - | - |
| Interest Coverage | -371746.74x | -30890.00x | -332.39x | -5.45x | -5.30x | 6.54x | -3.23x | -2.19x | -1216.44x | -6.00x |
| Total Equity | 8.61M | 6.65M | 16.17M | -8.35M | -18.84M | -4.54M | 982K | -1.76M | -4.57M | 9.98M |
| Equity Growth % | 1.02% | -0.23% | 1.43% | -1.52% | -1.26% | 0.76% | 1.22% | -2.79% | -1.6% | 3.18% |
| Book Value per Share | 326.33 | 196.86 | 321.66 | -127.72 | -230.68 | -40.98 | 6.96 | -9.34 | -11.70 | 12.37 |
| Total Shareholders' Equity | 8.61M | 6.65M | 16.17M | -8.35M | -18.84M | -4.54M | 982K | -1.76M | -4.57M | 9.98M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -20.45M | -23.07M | -35.47M | -56.46M | -92.76M | -101.05M | -110.04M | -115.83M | -122.33M | -117.54M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 653.92K | 374.01K | 0 | 0 | 0 | 0 | -2.06M | -2.01M | -1.74M | -1.74M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.63M | -2.51M | -2.89M | -15.29M | -22.31M | -22.57M | -7.43M | -7.26M | -9.38M | -6.33M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | -9.63% |
| Operating CF Growth % | -0.36% | 0.05% | -0.15% | -4.3% | -0.46% | -0.01% | 0.67% | 0.02% | -0.29% | 0.32% |
| Net Income | -2.62M | -2.38M | -9.93M | -23.46M | -31.62M | -1.3M | -8.21M | -5.8M | -6.5M | 4.8M |
| Depreciation & Amortization | 161.17K | 162.32K | 126.45K | 69.53K | 476.36K | 757.91K | 471K | 562K | 514K | 1.65M |
| Stock-Based Compensation | 191.2K | 327.29K | 149.16K | 69.53K | 1.07M | 2.95M | 2.76M | 1.6M | 1.14M | 682K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -176.31K | -756.95K | 7.67M | 7.12M | 7.64M | -25.17M | -3.15M | -4.08M | -3.89M | -13.57M |
| Working Capital Changes | -193.51K | 145.61K | -901.54K | 902.23K | 126.26K | 196.01K | 701K | 446K | -646K | 112K |
| Change in Receivables | -190.94K | 167.28K | -893.21K | 790.99K | 89.48K | -170.5K | 50.15K | 140K | -290K | 141K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 3K | 0 | 0 | -156K |
| Cash from Investing | -11.04K | -2.03M | 1.94M | -6.27M | -2.08M | -1.85M | -139K | -836K | -637K | -12K |
| Capital Expenditures | -8.73K | -5.19K | -1.3M | -6.35M | -2.15M | -1.91M | -139K | -836K | -637K | -12K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -2.31K | -2.02M | 3.35M | 74.07K | 66.6K | 61.29K | 0 | 0 | 0 | 0 |
| Cash from Financing | 8.66M | 0 | 17.77M | 22.55M | 24.68M | 4.27M | 21.43M | 6.78M | 1.09M | 3.44M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 8.66M | 0 | 17.77M | 0 | 20.4M | 304.35K | 392.62K | 26.51K | 947K | 1.44M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -2.64M | -2.51M | -4.18M | -21.64M | -24.47M | -24.48M | -7.57M | -8.1M | -10.02M | -6.35M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | -9.65% |
| FCF Growth % | -0.35% | 0.05% | -0.67% | -4.17% | -0.13% | -0% | 0.69% | -0.07% | -0.24% | 0.37% |
| FCF per Share | -100.21 | -74.34 | -83.25 | -331.11 | -299.59 | -220.88 | -53.60 | -42.97 | -25.65 | -7.87 |
| FCF Conversion (FCF/Net Income) | 1.01x | 1.05x | 0.29x | 0.65x | 0.71x | 16.28x | 0.90x | 1.25x | 1.44x | -1.32x |
| Interest Paid | 5.9K | 7.01K | 20.98K | 12.3K | 37.93K | 14K | 0 | 916K | 833K | 143K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -40.68% | -31.25% | -87.05% | -600.05% | - | - | -835.64% | - | - | 177.37% |
| Return on Invested Capital (ROIC) | -240.49% | -178.78% | - | - | - | 29.46% | -62.1% | -89.45% | -86.51% | -61.06% |
| Gross Margin | - | - | - | - | - | - | - | - | - | -88.15% |
| Net Margin | - | - | - | - | - | - | - | - | - | 728.88% |
| Debt / Equity | - | - | - | - | - | - | 29.77x | - | - | 0.21x |
| Interest Coverage | -371746.74x | -30890.00x | -332.39x | -5.45x | -5.30x | 6.54x | -3.23x | -2.19x | -1216.44x | -6.00x |
| FCF Conversion | 1.01x | 1.05x | 0.29x | 0.65x | 0.71x | 16.28x | 0.90x | 1.25x | 1.44x | -1.32x |
| 2024 | |
|---|---|
| License | 100K |
| License Growth | - |
Scinai Immunotherapeutics Ltd. (SCNI) has a price-to-earnings (P/E) ratio of 0.2x. This may indicate the stock is undervalued or faces growth challenges.
Scinai Immunotherapeutics Ltd. (SCNI) reported $1.1M in revenue for fiscal year 2024.
Scinai Immunotherapeutics Ltd. (SCNI) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Scinai Immunotherapeutics Ltd. (SCNI) is profitable, generating $4.6M in net income for fiscal year 2024 (728.9% net margin).
Scinai Immunotherapeutics Ltd. (SCNI) has a return on equity (ROE) of 177.4%. This is excellent, indicating efficient use of shareholder capital.
Scinai Immunotherapeutics Ltd. (SCNI) had negative free cash flow of $5.7M in fiscal year 2024, likely due to heavy capital investments.